MENU
You have 0 genes in your order Proceed to order
Your cart is empty

Genetic testing, powered for prostate cancer

Improve outcomes with genetic testing

ORDER NOW

The National Comprehensive Cancer Network® (NCCN®) recommends all patients with high-risk or metastatic prostate cancer consider germline genetic testing.1

Who should be considered for genetic testing?

According to the National Comprehensive Cancer Network® (NCCN®), germline genetic testing should be considered for the following patients:1

  • All men with high-risk, very high-risk, regional, or metastatic prostate cancer
  • All men with any stage prostate cancer and a family history consisting of any of the following:
    • Brother, father, or multiple family members diagnosed with prostate cancer at <60 years of age; OR
    • Family member with a known mutation; OR
    • More than one relative with breast, ovarian, or pancreatic cancer (suggests possibility of BRCA2 mutation); OR
    • More than one relative with colorectal, endometrial, gastric, ovarian, pancreatic, small bowel, urothelial, kidney, or bile duct cancer (suggests possibility of Lynch syndrome)

Genetic status impacts treatment decisions

Results from germline genetic testing may help guide medical management, including:1,2

  • Genetic counseling
  • Early use of platinum chemotherapy
  • Eligibility for clinical trials with PARP inhibitors
  • Eligibility for pembrolizumab (Keytruda®) in later lines of treatment (following microsatellite instability or mismatch repair deficiency)

Invitae Prostate Cancer Panel

Invitae offers comprehensive genetic testing for patients at risk for hereditary prostate cancer. More than 180,000 cases of prostate cancer are diagnosed each year; 5-10% of those are expected to be hereditary.2,3

Pathogenic variants in BRCA1 and BRCA2 are only part of the story. Invitae’s comprehensive prostate cancer panel targets up to 15 genes that evidence associates with a hereditary predisposition to prostate cancer:

ATM,  BRCA1,  BRCA2,  CHEK2,  EPCAM,  FANCA,  HOXB13,  MLH1,  MSH2,  MSH6,  NBN,  PALB2,  PMS2,  RAD51D,  TP53

Results are available in 10–21 calendar days (14 days on average).

VIEW PANEL

Invitae makes genetic testing easy

Support for you

Genetic counselors available to review cases and aid in interpreting results
Learn more

Support for patients

Genetic counselors on-hand to speak with your patients at no additional charge
Learn more

Test family members

Positive result? Test first-degree relatives at no additional charge within 90 days
Learn more

Simple pricing. Simple billing. No surprises.

  • Invitae is dedicated to accessible pricing, with no explanation of benefits >$1500 ever
  • Medicare and Medicaid accepted and Patient Assistance Program available to patients who meet the clinical and income criteria

A positive result has implications not only for treatment, but also for future cancer risk

Lifetime cancer risks for prostate cancer genes

1Referenced with permission from the NCCN: Prostate Cancer. Version 1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed February 26, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. 
2Pritchard, CC. et al. NEJM, 2016.
3Cancer Genome Atlas Research Network. Cell, 2015.
4Nicolosi, PLW et al. Presented at ASCO Annual Meeting; June 2017; Chicago, Illinois.

The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.